Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients who underwent PCI
• Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin
• No use of PCAB, PPI, or an H2-receptor within the past month
Locations
Other Locations
Republic of Korea
Samsung Medical Center
RECRUITING
Seoul
Contact Information
Primary
Ki Hong Choi, MD, PhD
cardiokh@gmail.com
82-2-3410-3419
Backup
Danbee Kang, PhD
dbee.kang@gmail.com
82-2-2148-7197
Time Frame
Start Date: 2024-10-22
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 100000
Treatments
Routine use of P-CAB
All-comer patients with P-CAB
Guideline-directed GI protection strategy
Use of PPI or not according to GI bleeding risk
Related Therapeutic Areas
Sponsors
Leads: Samsung Medical Center